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remains unclear. We performed post hoc analysis of outcome in patients from the BASE
ACS (A prospective randomized comparison of titanium-nitride-oxide-coated bioactive
stents with everolimus-eluting stents in acute coronary syndrome) trial who underwent PD
versus those who did not. The BASE ACS trial randomized 827 patients (1:1) with ACS to
receive either titanium-nitride-oxideecoated bioactive stents or everolimus-eluting stents.
The primary end point was major adverse cardiac events (MACE): a composite of cardiac
death, nonfatal myocardial infarction (MI), or ischemia-driven target lesion revasculari-
zation. Follow-up was planned at 12 months and yearly thereafter for up to 7 years. Of 827
patients enrolled in the BASE ACS trial, 357 (43.2%) underwent PD. Median follow-up
duration was 5 years. Patients who underwent PD had less frequent nonfatal MI events
at long-term follow-up, compared with those who did not (4.5% vs 8.5%, respectively, p[
0.02). The rates of MACE (15.7% vs 15.1%, respectively, p [ 0.81), and the other end-
points, were not signiﬁcantly different (p >0.5 for all). The results were consistent in pro-
pensity scoreematched analysis (270 pairs). In patients treated with bioactive stents, those
who underwent PD had a trend for a fewer nonfatal MI events (p[ 0.076). Comparably, in
patients treated with everolimus-eluting stents, MACE and all the individual end points
were comparable (p >0.5 for all). In conclusion, patients treated with early percutaneous
coronary intervention for ACS who underwent PD had less frequent nonfatal MI events at
long-term follow-up, compared with those who did not; MACE rates were not signiﬁcantly
different.  2016 Elsevier Inc. All rights reserved. (Am J Cardiol 2017;119:345e350)In the era of bare-metal stents, adjunctive post-dilation
(PD) with noncompliant balloons inﬂated at higher pres-
sure increased the ﬁnal minimal stent area and doubled the
frequency of optimal stent deployment.1 With modern stent
delivery systems, optimal stent deployment improved from
35.6% to 56.5% after PD in unselected patients.2 Stent
underexpansion independently predicted stent thrombosis
(ST) after sirolimus-eluting stent implantation.3 Likewise,
minimal stent area was smaller in patients with in-stent
restenosis after sirolimus-eluting stent implantation for
both de novo and restenotic lesions.4,5 Yet, the role of PD
after implantation of new-generation drug-eluting stents in
patients presenting with acute coronary syndrome (ACS)
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0.1016/j.amjcard.2016.09.057titanium-nitride-oxideecoated bioactive stents (BAS) in
unselected cohorts and in randomized trials of ACS.6e9 The
BASE ACS (A prospective randomized comparison of ti-
tanium-nitride-oxide-coated bioactive stents with ever-
olimus-eluting stents in acute coronary syndrome) trial
showed noninferiority of BAS versus everolimus-eluting
stents (EES) for the primary end point of major adverse
cardiac events (MACE) in patients with ACS, at long-term
follow-up.9e12 In post hoc analysis of the trial, we
explored the long-term clinical outcome of patients who
underwent PD versus those who did not.
Methods
The trial design was previously described.9 In short, the
BASE ACS trial was a prospective single-blinded random-
ized trial conducted in 14 centers. From January 2009 to
September 2010, we randomized 827 patients (1:1) present-
ing with ACS who underwent early percutaneous coronary
intervention to receive either BAS (Titan-2; Hexacath, Paris,
France) or EES (Xience V; Abbott Vascular, Santa Clara,
California). Follow-up was planned at 12 months and yearly
thereafter through 7 years. The trial was initiated by the
investigators and conducted according to the ethicalwww.ajconline.org
Table 1
Baseline clinical, angiographic and procedural characteristics of the 2 study
groups
Variable Post-Dilatation p Value
Yes (N ¼ 357) No (N ¼ 470)
Age (years) 63.6  11.3 62.5  12.3 0.19
Women 86 (24.1%) 112 (23.8%) 0.93
Diabetes mellitus 64 (17.9%) 76 (16.2%) 0.50
Current smoker 116 (32.5%) 162 (34.5%) 0.55
Hyperlipidemia 195 (54.6%) 193 (41.1%) <0.001
Hypertension 176 (49.3%) 237 (50.4%) 0.74
Presentation by ST
elevation myocardial
infarction
135 (37.8%) 186 (39.6%) 0.60
Stent used (BAS/EES) 49.6%/50.4% 51.1%/48.9% 0.67
Prior myocardial
infarction
39 (10.9%) 57 (12.1%) 0.59
Prior percutaneous
coronary intervention
35 (9.8%) 48 (10.2%) 0.84
Prior coronary bypass 16 (4.5%) 21 (4.5%) 0.99
ACC/AHA Lesion
type B/C
320 (89.6%) 411 (87.4%) 0.33
Thrombus 154 (43.1%) 210 (44.7%) 0.65
Calciﬁed lesions 178 (49.9%) 174 (37.0%) <0.001
Bifurcation lesions 84 (23.5%) 93 (19.8%) 0.19
Reference vessel diameter
(mm)
3.16  0.43 3.12  0.43 0.15
Lesion length (mm) 14.9  6.7 13.9  5.3 0.015
Stent diameter (mm) 3.18  0.44 3.12  0.44 0.08
Stent length (mm) 18.8  5.3 17.8  5.5 0.009
Total stent length per
lesion (mm)
21.9  8.9 19.8  8.7 0.001
Number of vessels treated
per patient
1.15  0.39 1.14  0.39 0.84
Number of lesions treated
per patient
1.20  0.52 1.18  0.49 0.59
Stents per culprit lesion 1.19  0.41 1.11  0.33 0.004
Direct stenting 85 (23.8%) 175 (37.2%) <0.001
Stent failure 2 (0.6%) 3 (0.6%) 1.00
Procedural success 355 (99.4%) 470 (100%) 0.18
Unfractionated heparin 78 (21.8%) 137 (29.1%) 0.018
Low-molecular weight
heparin
226 (63.3%) 257 (54.7%) 0.013
GP IIb IIIa inhibitor 99 (27.7%) 143 (30.4%) 0.39
Bivalirudin 45 (12.6%) 76 (16.2%) 0.15
Continuous variables are presented as mean  SD, whereas categorical
variables are presented as frequency (percentage).
ACC ¼ American College of Cardiology; AHA ¼ American Heart
Association; BAS ¼ bioactive stent; GP ¼ glycoprotein.
346 The American Journal of Cardiology (www.ajconline.org)guidelines of the 1964 Declaration of Helsinki, as revised in
2013. Informed written consent was obtained from every
patient after explanation of the trial protocol; the protocol was
approved by the ethics committees of the coordinating center
(Satakunta Central Hospital) and the other participating cen-
ters. The trial is registered under ClinicalTrials.gov, with
number NCT00819923.
Patients not previouslymaintained on aspirinwere pretreated
with aspirin at a loading dose of 250mg orally or 250 to 500mg
intravenously and continued at a dose of 75 to 150 mg daily
indeﬁnitely. Oral clopidogrel was initiated at a loading dose of
300 to 600 mg before or immediately after the procedure andcontinued at a dose of 75mg daily. Patients in either groupwere
prescribed clopidogrel for a minimum of 6 months and, there-
after, for extended periods (maximum 12 months) at operator’s
discretion. During the procedure, lowemolecular-weight or
unfractionated heparin was administered intravenously in the
standard dosage. Use of glycoprotein IIb and IIIa inhibitors or
bivalirudin was left to operator’s discretion.
PD was performed using a noncompliant balloon slightly
larger (0.25 to 0.5 mm) than the stent deployment balloon,
inﬂated at higher pressures (16 bars). The diagnostic
criteria for noneST-segment elevation ACS and ST-
segment elevation myocardial infarction (MI) were previ-
ously described.9 The primary end point was the ﬁrst
occurrence of MACE: a composite of cardiac death, nonfatal
MI, or ischemia-driven target lesion revascularization
(TLR). Secondary end points included noncardiac death and
deﬁnite ST. Cardiac death was deﬁned as death from car-
diovascular causes or any death without known cause. ST
was adjudicated according to the criteria of deﬁnite ST
described by the Academic Research Consortium.13 An in-
dependent clinical events committee whose members were
blinded to stent group allocation adjudicated all the indi-
vidual end points according to the prespeciﬁed deﬁnitions.
Continuous variables were presented as mean  SD,
whereas categorical variables were described with absolute
and relative (percentage) frequencies. Comparisons between
the 2 subgroups (patients who underwent PD vs those who
did not) were performed using the unpaired t test for
continuous variables and the Pearson chi-square test or
Fisher’s exact test for categorical variables, as appropriate.
Data analysis was based on the intention-to-treat principle.
We observed signiﬁcant differences between the 2 sub-
groups in several baseline characteristics. Therefore, we
performed a propensity scoreematched analysis of the 2
subgroups to estimate the impact of PD on the clinical
outcome. We calculated the propensity score using a logistic
regression model in which we included—as covariates—all
the baseline clinical, angiographic, and procedural variables
with a difference between the 2 subgroups as indicated by a
p <0.1 in univariate analysis. The unmatched subgroup
variable (PD vs non-PD) was entered in the model as the
dependent variable. Probabilities predicted by the model
were saved as a new variable: propensity score, which was
then used to identify and select the matched pairs. Hosmer-
Lemeshow test was used to assess the ﬁt of the logistic
regression model (chi-square: 12.18, p ¼ 0.143). Finally, we
used the “Caliper and Radius” matching method for selec-
tion of the matched pairs. Matching was performed based on
an estimated caliper width of 0.2 the SD of the propensity
score logit. Time-to-event curves were constructed using
Kaplan-Meier estimates, based on all the available follow-
up data for MACE, and were compared with the log-rank
test. Comparison of the 2 subgroups (based on PD) for the
clinical outcome was also performed stratiﬁed by stent
group. All tests were 2 sided and statistical signiﬁcance was
set at 5%. Data were analyzed with SPSS, version 16.
Results
Of the 827 patients enrolled in the BASE ACS trial, 357
(43.2%) underwent PD. Median follow-up duration was
Table 2
Clinical outcome in the 2 study groups at long-term follow-up
Outcome Event Post-Dilatation Hazard Ratio (95% CI) p Value
Yes (N ¼ 357) No (N ¼ 470)
MACE 56 (15.7%) 71 (15.1%) 1.05 (0.71 e 1.53) 0.81
Cardiac Death 15 (4.2%) 11 (2.3%) 1.83 (0.83 e 4.04) 0.12
Non-fatal MI 16 (4.5%) 40 (8.5%) 0.50 (0.28 e 0.92) 0.02
Ischemia-driven TLR 33 (9.2%) 36 (7.7%) 1.23 (0.75 e 2.01) 0.41
Non-cardiac Death 20 (5.6%) 17 (3.6%) 1.58 (0.82 e 3.07) 0.17
Deﬁnite ST 8 (2.2%) 10 (2.1%) 1.05 (0.41 e 2.69) 0.91
Variables are presented as frequency (percentage).
CI ¼ conﬁdence interval; MACE ¼ major adverse cardiac events; MI ¼ myocardial infarction; ST ¼ stent thrombosis.
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Figure 1. Kaplan-Meier estimates of the primary end point (a composite of cardiac death, nonfatal myocardial infarction, or ischemia-driven TLR) in the 2
subgroups at long-term follow-up.
Coronary Artery Disease/Post-dilatation in Acute Coronary Syndrome 3475.0 years; mean (SD) 4.2 years (1.9). Compared with those
who did not, patients who underwent PD were more often
dyslipidemic and had longer and more frequently calciﬁed
target lesions (p <0.05 for all). They underwent more often
pre-dilation and received longer stents, with more stents
per culprit lesion (p <0.05 for all). The other baseline
clinical, angiographic, and procedural data were matched
(Table 1).
Patients who underwent PD had less frequent nonfatal
MI events at long-term follow-up, compared with those who
did not (4.5% vs 8.5%, respectively, p ¼ 0.02). In patients
who underwent PD, 16 patients developed nonfatal MI
events: in 9 patients (56.3%), MI occurred while the patients
were still on dual antiplatelet therapy; in these, 5 events
(55.6%) occurred during the ﬁrst 30 days. In patients who
did not undergo PD, 40 patients developed nonfatal MI
events: in 18 patients (45%), MI occurred while the patientswere still on dual antiplatelet therapy; in these, 12 events
(66.7%) occurred during the ﬁrst 30 days. The cumulative
incidence of MACE was not signiﬁcantly different between
the 2 subgroups (15.7% vs 15.1%, respectively, p ¼ 0.81)
(Table 2, Figure 1). The rates of cardiac death and ischemia-
driven TLR were not signiﬁcantly different (p >0.05 both).
Deﬁnite ST and noncardiac death were not signiﬁcantly
different (p >0.05 both) (Table 2). Propensity score
matching yielded 540 patients (270 pairs) with balanced
baseline characteristics (Table 3). Consistently, in the pro-
pensity scoreematched pairs, patients who underwent PD
had less frequent nonfatal MI events, compared with those
who did not (3.7% vs 10.0%, respectively, p ¼ 0.004).
MACE and all the other individual end points were not
signiﬁcantly different between the 2 matched subgroups (p
>0.05 for all) (Table 4). In patients treated with BAS, those
who underwent PD had a trend for a fewer nonfatal MI
Table 3
Baseline clinical, angiographic and procedural characteristics of the 2
matched groups
Variable Post-Dilatation p Value
Yes (N ¼ 270) No (N ¼ 270)
Age (years) 63.9  10.7 62.3  12.3 0.096
Women 68 (25.2%) 67 (24.8%) 0.93
Diabetes mellitus 53 (19.6%) 43 (15.9%) 0.26
Current smoker 88 (32.6%) 85 (31.5%) 0.78
Hyperlipidemia 139 (51.5%) 129 (47.8%) 0.38
Hypertension 142 (52.6%) 132 (48.9%) 0.38
Presentation by ST
elevation myocardial
infarction
106 (39.3%) 96 (35.6%) 0.37
Stent used (BAS/EES) 52.2%/47.8% 53.7%/46.3% 0.73
Prior myocardial
infarction
33 (12.2%) 32 (11.9%) 0.89
Prior percutaneous
coronary intervention
29 (10.7%) 32 (11.9%) 0.68
Prior coronary bypass 14 (5.2%) 12 (4.4%) 0.68
ACC/AHA Lesion
type B/C
239 (88.5%) 241 (89.3%) 0.78
Thrombus 118 (43.7%) 115 (42.6%) 0.79
Calciﬁed lesions 124 (45.9%) 118 (43.7%) 0.60
Bifurcation lesions 61 (22.6%) 65 (24.1%) 0.68
Reference vessel
diameter (mm)
3.13  0.42 3.15  0.43 0.52
Lesion length (mm) 14.3  5.6 14.3  5.5 0.94
Stent diameter (mm) 3.15  0.44 3.16  0.45 0.90
Stent length (mm) 18.5  5.2 18.3  5.6 0.70
Total stent length per
lesion (mm)
21.1  8.9 21.1  9.4 0.91
Number of vessels treated
per patient
1.13  0.36 1.14  0.39 0.73
Number of lesions treated
per patient
1.17  0.44 1.18  0.50 0.85
Stents per culprit lesion 1.16  0.39 1.16  0.37 0.82
Direct stenting 79 (29.3%) 67 (24.8%) 0.24
Stent failure 1 (0.4%) 3 (1.1%) 0.62
Procedural success 269 (99.6%) 270 (100%) 1.00
Unfractionated heparin 68 (25.2%) 63 (23.3%) 0.61
Low-molecular weight
heparin
166 (61.5%) 175 (64.8%) 0.42
GP IIb IIIa inhibitor 72 (26.7%) 84 (31.1%) 0.25
Bivalirudin 34 (12.6%) 31 (11.5%) 0.69
Continuous variables are presented as mean  SD, whereas categorical
variables are presented as frequency (percentage).
ACC ¼ American College of Cardiology; AHA ¼ American Heart
Association; BAS ¼ bioactive stent; EES ¼ everolimus-eluting stent;
GP ¼ glycoprotein.
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respectively, p ¼ 0.076). MACE and the other end points
were not signiﬁcantly different (p >0.05 for all). Compa-
rably, in patients treated with EES, MACE and all the in-
dividual end points were not signiﬁcantly different (p >0.5
for all).
Discussion
The current post hoc analysis of the BASE ACS trial
demonstrated that patients treated with early percutaneous
coronary intervention for ACS who underwent PDfollowing the index procedure had less frequent nonfatal MI
events at long-term follow-up, compared with those who did
not; such better outcome persisted after propensity scoree
matched analysis. Moreover, the incidence of MI was
slightly lower in patients who underwent PD after BAS
implantation; yet, such incidence was comparable (between
those who underwent PD and those who did not) after EES
implantation. The current report is the ﬁrst to address the
impact of PD on the long-term clinical outcome after stent
implantation in patients with ACS.
Drug-eluting stents effectively reduced restenosis rates
and obviated the need for TLR in most patients who un-
derwent percutaneous coronary intervention in contempo-
rary clinical practice. Because PD was not routinely
performed in trials that conﬁrmed the efﬁcacy of DES, the
role of PD after drug-eluting stent implantation has ulti-
mately come into question. In clinical practice, PD is usually
operator decided and is rarely performed as a standard
procedure. A few studies reported the angiographic and
clinical outcome of high-pressure balloon PD after drug-
eluting stent implantation. In an early study of unselected
patients (n ¼ 6,479) who underwent drug-eluting stent im-
plantation, operator-decided PD was associated with
reduction of in-stent and in-segment late lumen loss and
binary restenosis rates at 7-month follow-up; yet, the rates of
overall and individual MACE (death, MI, and TLR) were
similar; ST rates were similar.14 In a more recent study,
unselected patients who underwent routine PD after
drug-eluting stent implantation (n ¼ 279, nearly 55% ﬁrst-
generation drug-eluting stents) were compared with histor-
ical controls who underwent ad hoc PD for suboptimal
results (n ¼ 262, 32% PD). The former group demonstrated
better immediate angiographic outcome versus the latter; at
12-month follow-up, routine PD was associated with lower
rates of MACE (death, MI, target vessel revascularization,
deﬁnite/probable ST), TLR, and target vessel revasculari-
zation; however, MI included cases of periprocedural MI
that were frequent in both groups (8.2% vs 8.4%, respec-
tively).15 Another study explored the outcome of operator-
decided PD in patients with ST-elevation MI (n ¼ 191)
who underwent primary percutaneous coronary intervention
with drug-eluting stents: compared with those who did not,
patients who underwent PD had less often target vessel
revascularization and deﬁnite/probable ST at 6-month
follow-up; yet, the 2 groups had similar immediate angio-
graphic outcome (Thrombolysis In Myocardial Infarction
ﬂow, myocardial blush).16 Nevertheless, no propensity score
matching was performed in the aforementioned studies (2 of
which are small sized); the comparison groups remained
unmatched for several key baseline characteristics. More-
over, outcome was reported at mid-term follow-up. Two
other retrospective studies suggested worse outcome in pa-
tients who underwent PD, versus those who did not. In post
hoc analysis of the National Heart, Lung, and Blood Insti-
tute Dynamic Registry, patients who presented with acute
MI and underwent PD had a higher risk of death/MI at
1 year compared with non-PD, and repeat revascularization
was similar; in those who presented without acute MI,
outcome was similar.17 In large registry data, PD was
associated with a higher restenosis risk, similar ST risk, but
a lower death risk.18 In the current post hoc analysis of a
Table 4
Clinical outcome in the 2 matched groups at long-term follow-up
Outcome Event Post-Dilatation Hazard Ratio (95% CI) p Value
Yes (N ¼ 270) No (N ¼ 270)
MACE 40 (14.8%) 44 (16.3%) 0.89 (0.56 e 1.42) 0.63
Cardiac Death 10 (3.7%) 7 (2.6%) 1.45 (0.54 e 3.85) 0.46
Non-fatal MI 10 (3.7%) 27 (10.0%) 0.35 (0.16 e 0.73) 0.004
Ischemia-driven TLR 24 (8.9%) 18 (6.7%) 1.37 (0.72 e 2.58) 0.33
Non-cardiac Death 16 (5.9%) 9 (3.3%) 1.83 (0.79 e 4.21) 0.15
Deﬁnite ST 6 (2.2%) 4 (1.5%) 1.51 (0.42 e 5.42) 0.52
Variables are presented as frequency (percentage).
CI ¼ conﬁdence interval; MACE ¼ major adverse cardiac events; MI ¼ myocardial infarction; ST ¼ stent thrombosis; TLR ¼ target lesion
revascularization.
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incidence of nonfatal MI at long-term follow-up versus
those who did not, both in crude and propensity scoree
matched analysis. The incidence of deﬁnite ST was com-
parable between the 2 groups, both in crude and matched
analysis. Cases of probable ST (acute MI in the index vessel
territory or cardiac death within 30 days of the index pro-
cedure) could have contributed to the discrepancy between
the relative rates of nonfatal MI and deﬁnite ST between the
2 comparison groups. Interestingly, the 6-month incidence
of deﬁnite/probable ST was lower with PD in patients with
ST-elevation MI who underwent primary percutaneous
coronary intervention with drug-eluting stents.16
Stent underexpansion is common and portends a high
risk of ST and restenosis after implantation of ﬁrst-
generation drug-eluting stents.3e5,19 Stent underexpansion
is related to acute strut malapposition immediately after
stent implantation.20 Stent segments with acute malap-
position portend a higher risk of delayed neointimal strut
coverage and late malapposition, compared with well-
apposed segments at implantation.21 Moreover, thrombus
resolution underneath the implanted stent might occur in
patients treated for ACS, further contributing to late strut
malapposition. In a study by intravascular ultrasound
at long-term follow-up, late acquired malapposition could
be attributed to positive vessel remodeling and/or plaque/
thrombus resolution.22 In a meta-analysis of 17 studies
with intravascular ultrasound performed at 6 to 9 months,
the risk of (very) late ST was sixfold higher in patients
with, versus those without, late malapposition (late acquired
or persistent).23 Moreover, in 2 recent studies by optical
coherence tomography, strut malapposition was the most
common identiﬁable mechanism in patients presenting
by late and very late ST after drug-eluting stent
implantation.24,25
The BASE ACS trial was not designed a priori to explore
speciﬁc differences in outcome based on PD following the
index procedure. Because of the retrospective nature of this
post hoc analysis, some data relevant to the outcome might
have been missed. In addition, the trial cohort is under-
powered for speciﬁc subgroup analysis. Moreover, analysis
of patient data in 1 subgroup that includes different stent
designs should be interpreted with caution. Furthermore, the
current post hoc analysis was a nonrandomized subgroup
analysis: the trial cohort was not randomized based on theindex subgroup analysis (PD versus non-PD), but instead,
PD was performed ad hoc, based on operator decision; this
might limit the conclusiveness of the results. Finally,
medication use was reported only at baseline, but not at
different time points of follow-up; this might have potential
effect on the results.Acknowledgment: The authors thank Tuija Vasankari, Eija
Niemelä, and Minna Ampio for their support in the conduct
of this study.
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